Navigation Links
New STELARA data show inhibition of joint destruction in active psoriatic arthritis
Date:10/28/2013

San Diego, October 28, 2013 -- New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo. Pre-specified integrated analyses from the PSUMMIT I and II trials showed treatment with either STELARA 45 mg or 90 mg resulted in significantly less change from baseline at week 24 in total psoriatic arthritis modified van der Heijde-Sharp (vdH-S) scores compared with placebo. STELARA-treated patients from the combined data analysis of both trials demonstrated continued inhibition through one year and through two years according to findings from the PSUMMIT I trial. These results are being presented during the 2013 Annual Meeting of the American College of Rheumatology (ACR). STELARA recently received approval from the U.S. Food and Drug Administration (FDA) and approval from the European Commission for the treatment of signs and symptoms in adult patients with active psoriatic arthritis.

"Data from the integrated analysis of the Phase 3 clinical program show the efficacy of the interleukin-12/23 antibody STELARA in inhibiting the progression of structural damage in patients with active psoriatic arthritis," said Iain B. McInnes, PhD, FRCP, Professor of Medicine, and Director of the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Scotland, lead study investigator. "These new findings are significant since impeding further joint damage is an important part of the long-term management of this chronic inflammatory disease."

According to a pre-specified integrated analysis of the two Phase 3 Multicenter, Randomised, Double-blind, Placebo-controlled trials of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis (PSUMMIT I
'/>"/>

Contact: Brian Kenney
BKenney1@its.jnj.com
215-628-7010
Tonic Life Communications USA
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Alzheimer's Pilot Study Proposed for Ustekinumab (Stelara)
2. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
3. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
4. Novel test identifies patients most likely to benefit from ALK inhibition therapy
5. Neurological Wellness Center's Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer's, Stroke and Brain Injury is Now Being Taught in a Newly Released Video
6. Epoxide hydrolase inhibition and Thiazolidinediones: A therapy for cardiometabolic syndrome
7. Joint-Replacement Failure Rate Higher for Smokers: Studies
8. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
9. Obesity, Diabetes May Raise Complications After Joint Replacement
10. Oxford University Press acquires joint ownership of Journal of Surgical Case Reports
11. Joint Replacement Boosts Heart Attack Risk Right After Surgery: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Kansas (PRWEB) November 26, 2014 ... will showcase expanded capabilities at RSNA 2014 in ... access, manage and share diagnostic images, photos, videos ... to Perceptive’s booth #8107 will learn more about ... newly acquired technologies and partner initiatives – that ...
(Date:11/26/2014)... who enter puberty early are at increased risk for ... linked with a number of factors associated with depression, ... to the researchers. Early puberty was also linked to ... and having friends who were prone to getting into ... an association between early puberty and these factors, it,s ...
(Date:11/26/2014)... of emergency department visits in the United States rose from ... in 2011, according to the U.S. Centers for Disease Control ... were going to ERs with non-urgent medical needs: 96 percent ... hours of arriving at the ER. In 2010, that number ... of patients arrived at the ER after normal business hours ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, 2014 (HealthDay ... disrupt the makeup of bacteria in the digestive system, potentially ... new study suggests. The research doesn,t confirm that ... and study authors aren,t recommending that anyone stop taking the ... used at the lowest dose that provides adequate relief of ...
(Date:11/24/2014)... From embedded sensors and biometrics to elite training ... take center stage at the FitnessTech Summit , presented ... 2015 International CES® , January 6, 2015 in Las Vegas ... The bond between fitness and technology is stronger than ever ... more about the human body. , “Fitness technology has become ...
Breaking Medicine News(10 mins):Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:ER Visits on the Rise, Study Reports 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4
... - Nuvo Research Inc.,(TSX: NRI), a Canadian ... and,development of drug products delivered to and ... drug delivery technologies, and Paladin Labs Inc.,(TSX: ... today,announced modifications to their existing licensing arrangements ...
... Social Security Disability Insurance Should Know Their Income History; Allsup Answers ... ... 8, 2008 -- People who find themselves with a mental or ... the emotional struggle to accept that they no longer can work. ...
... Services® (PPS®), renowned for its award-winning ... an on-demand, interactive case study, Beyond ... for Mid-Face Volumizing, now available on ... explores treatment options for the use ...
... With Only the Best Medical Travel Agencies , ... Vernon Hills, Illinois ... heats up in the U.S., more and more medical tourism agencies (MTAs) ... hospitals should be aware that not all MTAs are created equally. According ...
... Consumer-driven health plans (CDHP) -- hailed since their ... control costs -- are resulting in members forgoing ... problems, according to two newly published studies. , ... out-of-pocket or from a dedicated health-care account before ...
... Research,Center challenged a team of elite climbers to scale ... efforts of researchers to eliminate,cancer as a cause of ... on the Big Expedition for Cancer Research has,recently returned ... the 7,800-foot level of an unclimbed, unnamed peak, as ...
Cached Medicine News:Health News:Nuvo Research and Paladin announce amendments to Pennsaid and Pennsaid Plus agreements 2Health News:Nuvo Research and Paladin announce amendments to Pennsaid and Pennsaid Plus agreements 3Health News:Past Earnings Play Role in Determining SSDI Benefits 2Health News:Past Earnings Play Role in Determining SSDI Benefits 3Health News:Past Earnings Play Role in Determining SSDI Benefits 4Health News:Past Earnings Play Role in Determining SSDI Benefits 5Health News:AestheticEnhance.org Launches CME-Certified Case Study on Mid-Face Volumizing 2Health News:AestheticEnhance.org Launches CME-Certified Case Study on Mid-Face Volumizing 3Health News:An American Appeal to Overseas Hospitals 2Health News:Members of consumer-driven health plans choosing less care 2Health News:Inaugural Big Expedition for Cancer Research Encounters Mountain As Challenging As Finding a Cure for Cancer 2Health News:Inaugural Big Expedition for Cancer Research Encounters Mountain As Challenging As Finding a Cure for Cancer 3Health News:Inaugural Big Expedition for Cancer Research Encounters Mountain As Challenging As Finding a Cure for Cancer 4
(Date:11/26/2014)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that ... investor conferences.  , 31 st NASDAQ Investor ... 2, 2014 at 6:45 a.m. EST / 11:45 a.m. GMT. ... will provide an overview of the company and a business and ... Conference in New York, NY on Tuesday, ...
(Date:11/26/2014)... 26, 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the appointment of Ms. Rebecca Yingnan Zhang ... Ms.Zhang has over 20 years of experience ... 1999. Prior to Ms. Zhang,s appointment as the Company,s ...
(Date:11/24/2014)... DIEGO , Nov. 24, 2014  Arena Pharmaceuticals, Inc. ... scheduled to present a corporate overview and update at the ... December 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. ... New York . A live audio ... relations section of Arena,s website at www.arenapharm.com . A ...
Breaking Medicine Technology:Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3
... -- Tongjitang Chinese Medicines Company ("Tongjitang" or the "Company"; ... of its acquisition by Hanmax Investment Limited, a British ... Limited, a company incorporated in Hong Kong ("Fosun"). As ... wholly owned subsidiary of Hanmax and Fosun. Hanmax is ...
... two-year retrospective cohort study presented at the 63rd Annual ... U.S., showed that patients were significantly more likely to ... chronic ischemic heart diseases after an initial diagnosis of ... "These findings suggest a significant association between a ...
Cached Medicine Technology:Tongjitang Chinese Medicines Company Announces Closing of Merger and Intent to Delist from the NYSE 2Tongjitang Chinese Medicines Company Announces Closing of Merger and Intent to Delist from the NYSE 3New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease 2New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease 3
The new CR6-45NM non-mydriatic retinal camera is an ideal diagnostic tool for ophthalmologists, optometrists and other medical professionals, especially when it comes to detecting and monitoring diab...
An ideal choice for film photography. The new TRC-50FXC provides 35mm color and Polaroid capability....
Digital imaging for optical screening: Diabetes, glaucoma macular degeneration, and other retinal disease....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Medicine Products: